Schwartz G J, Mehta R H, Wenig B L, Shaligram C, Portugal L G
Department of Otolaryngology-Head and Neck Surgery, University of Illinois at Chicago, 1855 West Taylor Street, Chicago, IL 60612, USA.
Head Neck. 2000 Jan;22(1):34-41. doi: 10.1002/(sici)1097-0347(200001)22:1<34::aid-hed6>3.0.co;2-3.
Squamous cell carcinoma (SCCA) of the oral cavity recurs with a frequency of 25%-48%, a fact that usually portends a poor prognosis. Recent studies have reported salvage cure rates as high as 67%. Investigators have also claimed that restaging recurrent tumors provides useful prognostic information, although this has not been demonstrated with tumors of the oral cavity. The purposes of this study were: (1) to report the patterns of recurrent SCCA of the oral cavity; (2) to examine the benefit of restaging oral cavity tumors, and (3) to compare different treatment modalities in the management of recurrent SCCA of the oral cavity. Materials and Methods Thirty-eight patients who developed recurrent SCCA of the oral cavity were reviewed. Salvage treatment consisted of surgery, chemotherapy, radiation therapy, or a combination of these modalities. Survival analysis was based on the stage of the primary and recurrent tumors and the type of salvage treatment received.
The overall recurrence rate was 28%. Local recurrence was most common (58%) followed by locoregional (27%) and regional recurrence (16%). Patients who recurred more than 6 months after completion of their primary treatment had improved survival compared with those who recurred within 6 months of initial treatment. Individuals with stage I-II primary tumors had significantly improved salvage time and total survival time compared with those with stage III-IV primary tumors (p < 0.005 and p < 0.001). Conversely, the stage of the recurrent tumor was not predictive of either improved salvage time or total survival time. Patients who underwent salvage surgery had significantly improved salvage time and total survival time compared with those who received chemotherapy and/or radiation therapy (p < 0.001 and p < 0.002). The overall salvage cure rate was 21%. Neither the stage of the primary or recurrent tumors nor the type of salvage treatment received significantly correlated with an improved cure rate. However, the group of patients who underwent salvage surgery approached a statistically significant improvement in cure rate (p = 0.08).
Squamous cell carcinoma of the oral cavity is most likely to recur at the primary site. The stage of the primary tumor is significantly correlated with survival even after recurrence, but the stage of the recurrent tumor is not significantly correlated with survival. Patients most likely to benefit from retreatment are those who (1) have primary tumors stage I-II, (2) recur greater than 6 months after their initial treatment, and (3) develop recurrences that are amenable to salvage surgery.
口腔鳞状细胞癌(SCCA)的复发率为25%-48%,这一事实通常预示着预后不良。最近的研究报告挽救治愈率高达67%。研究人员还声称,对复发性肿瘤进行重新分期可提供有用的预后信息,尽管在口腔肿瘤中尚未得到证实。本研究的目的是:(1)报告口腔复发性SCCA的模式;(2)检查对口腔肿瘤进行重新分期的益处;(3)比较口腔复发性SCCA治疗中的不同治疗方式。材料与方法回顾了38例发生口腔复发性SCCA的患者。挽救治疗包括手术、化疗、放疗或这些方式的联合应用。生存分析基于原发肿瘤和复发性肿瘤的分期以及所接受的挽救治疗类型。
总体复发率为28%。局部复发最为常见(58%),其次是局部区域复发(27%)和区域复发(16%)。与在初始治疗后6个月内复发的患者相比,在完成初始治疗6个月后复发的患者生存率有所提高。与原发肿瘤为III-IV期的患者相比,原发肿瘤为I-II期的患者挽救时间和总生存时间显著延长(p<0.005和p<0.001)。相反,复发性肿瘤的分期并不能预测挽救时间或总生存时间的改善。与接受化疗和/或放疗的患者相比,接受挽救性手术的患者挽救时间和总生存时间显著延长(p<0.001和p<0.002)。总体挽救治愈率为21%。原发肿瘤或复发性肿瘤的分期以及所接受的挽救治疗类型均与治愈率的提高无显著相关性。然而,接受挽救性手术的患者组治愈率有接近统计学显著提高的趋势(p=0.08)。
口腔鳞状细胞癌最有可能在原发部位复发。即使在复发后,原发肿瘤的分期也与生存率显著相关,但复发性肿瘤的分期与生存率无显著相关性。最有可能从再次治疗中获益的患者是那些:(1)原发肿瘤为I-II期;(2)在初始治疗6个月后复发;(3)复发适合进行挽救性手术的患者。